Cingulate Inc. announced that its wholly owned subsidiary, Cingulate Therapeutics LLC, amended the employment agreement for Matthew N. Brams, Executive Vice President and Chief Medical Officer,<pad> extending his full-time employment trial period from June 30, 2026, to September 30, 2026. Additionally, the company<pad> announced its selection for membership in the Russell 3000E Index. Cingulate Inc. is a biotechnology company.
